Abstract:Carbenoxolone (CBX) is the active principle of licorice, which is used to treat psoriasis, peptic ulcers, and wound healing. However, there is no report on how CBX ameliorates hepatic lipid metabolism and inflammation in obese mice. In this study, our aim is to explore the mechanism by which CBX regulates lipid metabolism in the liver of obese mice. C57BL/6J mice were divided into three groups and were fed with normal chow diet (NC group) or High-fat diet (HFD and CBX group) for eight weeks. Then mice in CBX group were given CBX every day by gavage for twelve weeks (15 mg/kg). Blood was collected for detection of triglycerides (TG), total cholesterol (TC), density lipoprotein (LDL), high-density lipoprotein (HDL), Alanine aminotransferase (ALT), and Aspartate aminotransferase (AST). Liver tissues were stained with hematoxylin-eosin for histological examination. Immunohistochemical staining was performed for detection of SOCS-3 (Suppressor of cytokine signaling 3), SREBP-1 (Sterol regulatory element-binding protein 1), and FAS (Fatty acid synthase) protein. The genes of SOCS-3, SREBP-1, and FAS in liver were assessed by real-time PCR. Western blotting was applied to detect the protein expressions of the phosphorylated JAK2 (Janus kinase 2) and phosphorylated STAT3 (Signal transducer and activator of transcription 3). Our results showed that compared with the HFD group, serum concentrations of TG, TC and LDL were decreased significantly, while the concentration of HDL was increased in the CBX group. CBX could attenuate intracellular lipid accumulation in the liver. Besides, treatment with CBX could significantly decrease levels of inflammatory factors such as IL-6 (Interleukin 6) and TNF-a (Tumor necrosis factor-a), increase expressions of phosphorylated JAK2 and phosphorylated STAT3, decrease the expressions of SOCS-3, SREBP-1 and FAS in the liver. In conclusion, through activating the JAK2/STAT3 signaling pathway in liver and reducing the expression of SCOCS-3, CBX could further decrease the expressions of SREBP-1c, FAS and ameliorate the inflammatory state of liver, so as to protecting the liver from lipid metabolism damage induced by high-fat diet. Therefore, CBX has the possibility for the treatment of obesity, hyperlipidemia, and inflammation.

Bicyclol Attenuates Obesity-Induced Cardiomyopathy via Inhibiting NF-κB and MAPK Signaling Pathways

Bicyclol alleviates obesity-induced renal injury by inhibiting JNK and NF-κB-mediated inflammation

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice

Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice

Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

Bicyclol Alleviates Atherosclerosis by Manipulating Gut Microbiota (Small 9/2022)

Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine

Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation

Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway

Cyy-272, an indazole derivative, effectively mitigates obese cardiomyopathy as a JNK inhibitor

Schisandrin B Ameliorated Chondrocytes Inflammation and Osteoarthritis Via Suppression of NF-κB and MAPK Signal Pathways.

Bicyclol Alleviates Signs of BDL-Induced Cholestasis by Regulating Bile Acids and Autophagy-Mediated HMGB1/p62/Nrf2 Pathway

Schisandrin B Regulates Lipid Metabolism in Subcutaneous Adipocytes

Bicyclol Protects Cardiomyocytes From Apoptosis In Ischemia/Reperfusion Injury Via Inhibition Of Tlr4/Nf-Kappa B Pathway

Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway

Bofutsushosan ameliorates obesity in mice through modulating PGC-1α expression in brown adipose tissues and inhibiting inflammation in white adipose tissues

Cyy-287, a novel pyrimidine-2,4-diamine derivative, efficiently mitigates inflammatory responses, fibrosis, and lipid synthesis in obesity-induced cardiac and hepatic dysfunction

Carbenoxolone ameliorates hepatic lipid metabolism and inflammation in obese mice induced by high fat diet via regulating the JAK2/STAT3 signaling pathway

Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation

Isoginkgetin, a Bioactive Constituent from Ginkgo Biloba, Protects Against Obesity-Induced Cardiomyopathy Via Enhancing Nrf2/ARE Signaling.

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease